

## PROPOSAL INNOVATIVE PROBIOSOMIAL TECNOLOGY FOR STRENGTHENING OF THE IMMUNE SYSTEM

Bruno Riccardi <sup>1\*</sup>, Tomas De Paoli <sup>2</sup>, Sergio Resta <sup>3</sup>

1. *Representative Lipotech, 56022 Castelfranco di Sotto (PI), Via dei Lazzeri, 33, Italy.*
2. *Lipotech's President, Parque Industrial La Cantabrica, Tres Arroyos 329 1706 Haedo - Buenos Aires, Republica Argentina.*
3. *Surgeon, general surgery specialist, freelancer, 53043 Chiusi (SI), Via Montegrappa 1, Italy*

### ARTICLE INFO

#### Received:

20 Mar 2020

#### Received in revised form:

17 Jun 2020

#### Accepted:

19 Jun 2020

#### Available online:

28 Jun 2020

**Keywords:** Infectious diseases, CoVID19, Immune defense, Nutrigenomic, Microbiome, Probiosomial technology

### ABSTRACT

The frequent spread of infectious diseases, viral or bacterial that continually affects our world, poses the need to adopt increasingly powerful methods to overcome the ability of pathogens to adapt, evolve and reduce the effectiveness of traditional therapies. The recent pandemic from Covid19 has highlighted in all its drama because traditional methods of treatment cannot overcome the pathogenic load of this virus and even less will succeed in winning the next pandemics. This manuscript proposes a holistic approach in the fight against infections, which in addition to dealing with the pathologies in place with the traditional strategies of care and prevention, is aimed primarily at strengthening the immune system of people, using advanced technologies to achieve maximum effectiveness.

Copyright © 2013 - All Rights Reserved - Pharmacophore

**To Cite This Article:** Bruno Riccardi, Tomas De Paoli, Sergio Resta, (2020), "Proposal Innovative Probiosomial Tecnology for Strengthening of the Immune System", *Pharmacophore*, **11(3)**, 38-46.

### Introduction

The recent pandemic caused by CoVID19 has increased awareness of our vulnerability and unpreparedness to cope with the sudden and unpredictable spread of unknown infectious diseases. Since the 1918 Spanish flu pandemic, several infectious diseases caused by various types of viruses have occurred, with a constant temporal frequency, and it has resulted in numerous victims. In our globalized world, the spread of infectious diseases is facilitated by international trade or cultural exchanges involving very close and frequent interpersonal contacts.

Without going back over the history of infectious diseases that have occurred in this century, if we limit to the cases of the common influence that has affected the world population in the last 10 years, we discover that it has produced millions of victims.

Proper nutrition is essential for health and proper functioning of all systems in the body, including the immune system [1]. Despite developments in knowledge and technological advances in the biomedical field, even today we are not able to provide valid and effective tools to defend ourselves against viral or bacterial infections. A well-known example is the increasing occurrence of bacterial diseases caused by resistant antibiotic pathogens.

This depends above all on the intrinsic properties common to all bacterial and viral pathogens: their extraordinary ability to adapt to the different environmental conditions, external or internal to the host, which guarantees their multiplication and survival. The high rate of evolution allows pathogens to evade, in a few generations, the methods adopted to combat them. On February 17, 2020, the Chinese State Council confirmed that chloroquine phosphate, an old drug for the treatment of malaria, had demonstrated a tangible and safe activity in treating pneumonia related to COVID-19 [2].

For this capacity of evolution, bacteria and viruses, have very small, genetically distinguishable differences even between strains belonging to the same species, which are important for the typing their virulence factors. This increases the difficulty

**Corresponding Author:** Bruno Riccardi, Representative Lipotech, 56022 Castelfranco di Sotto (PI), Via dei Lazzeri, 33, Italy. Email: lipotech.br@gmail.com

of their isolation and treatment and explains why antibiotic and antiviral therapies, with time, have less and less efficacy and transient.

### Characterization of the CoVID19

The CoVID19 has several virulence factors, with different pathogenic capacity.

Coronaviruses are large, enveloped, positive-stranded RNA viruses. The genome is packed inside a helical capsid formed by the nucleocapsid protein and further surrounded by an envelope with three structural proteins: the membrane, the envelope, involved in virus assembly, and spike protein mediates virus entrance into host cells.

Spike is a critical determinant of viral host range and tissue tropism and a major inducer of host responses immune.

Exist at least two different kinds of CoVID viruses exist, designated *L* and *S*. Although the *L* type (70%) is more prevalent and more aggressive than the *S* type (30%), the *S* type was found to be the ancestral version. It is important to keep in mind that viruses mutate all the time and not all mutations are indicative of increased disease severity or transmission rates. Knowing the exact number of strains (or types) of the virus is crucial because, to be effective, the eventual vaccine will have to target features present in all known strains (or types).


The most important clinical manifestations of the Coronavirus disease 2019 (CoVID-19) are *Acute respiratory failure and a systemic coagulopathy*. These are critical aspects of the morbidity and mortality characterizing infection with severe acute respiratory distress syndrome associated with Coronavirus-2, CoVID-19. [3].

Moreover, CoVID-19 may predispose to both venous and arterial thromboembolic disease due to excessive inflammation, hypoxia, immobilization, and diffuse intravascular coagulation (DIC). [4]

In fact, in addition to the most obvious clinical manifestations, that include cough, fever, and shortness of breath major events usually observed in CoVID-19 patients, other events: e.g., high blood pressure, arterial and venous thromboembolism, kidney disease, etc., indicate that the virus is affecting the endothelium, one of the largest organs in the human body. [5-10]

Endothelial dysfunction is a major determinant of CoVID-19. The SARS-CoV-2 coronavirus accesses host cells via the binding of its spike glycoprotein to angiotensin-converting enzyme 2 (ACE2), sialic acid receptor, transmembrane serine protease 2 (TMPRSS2), and extracellular matrix metalloproteinase inducer (CD147); cathepsin B and L also participate in virus entry. All of these factors are expressed in endothelial cells. Endothelial dysfunction is a common feature of the clinical manifestations observed in CoVID-19 patients. All of the drugs proposed as a potential therapeutic strategy to treat CoVID-19 patients have been shown to improve endothelial function, including tocilizumab, colchicine, chloroquine, hydroxychloroquine, azithromycin, and famotidine.

There are numerous therapeutic proposals for the CoVID19, in addition to those mentioned, the world's biomedical research is testing different solutions. But of proven effectiveness, there is still nothing. It will take some more time and a lot of clinical trials before obtaining certain results. In my opinion, using only these tools, we will never reach the final solution, the "Panacea" (from the Greek Πανάκεια, Panákeia: universal and all-powerful healing) of all infectious diseases. Therefore it is obvious to everyone, that the solution to deal with infectious diseases cannot be entrusted to drug therapy alone, but must be associated with other treatments, whit a holistic approach. We can trace the relationships between the factors involved in the spread of infectious diseases with the following diagram, Fig. 1.



**Fig. 1.** Relationship between Pathogens-Hosts- Environment

Fortunately, we can act on all three factors involved in the transmission of infections, so they are called "modifiable factors". The environmental factor is the easiest to control: it is the first intervention adopted worldwide against the pandemic by CoVID19 with the adoption of hygienic measures, hand washing, protective barriers (masks), and interpersonal isolation (quarantine). The intervention is certainly effective but requires an important change in habits and significant people's restriction in the movement and freedom, and cannot be prolonged indefinitely.

Another factor on which to intervene is the pathogen itself, and for this reason, many research laboratories are committed worldwide to find an effective means to defeat it. However, as mentioned above, because of the evolution and development of resistance by pathogens, the effectiveness of this intervention has always been partial and transitory.

The best strategy to adopt is to act simultaneously on all pathogenetic factors, but with a particular focus on the target of infection: the host. The host is the final link in the infectious chain, and the ultimate recipient pathogen's propagation and its healing can stop their survival and spread.

**Why Boost Immune System**

In combination with the prevention measures described above, an effective method for the host's protection, consisting of strengthening the host's immune Innate and Acquired defenses.

**The immune system:** has different levels of response:

**Physical barriers of the Host:**

Consisting of superficial epithelial coatings, mucus, and other secretions containing anti-microbial molecules, internal anatomical barriers (pleura, peritoneum, bands, etc.).

**Innate immune response:**

produced by "sentinel" cells residing in tissues (mast cells, macrophages, dendritic cells) "emergency response" cells coming from circulating blood (neutrophils, monocytes, and derivatives, eosinophils, NK-Natural Killer cells); soluble mediators (Ab: Antigen binding, natural, complement, acute phase proteins).

**Acquired immune response:**

Produced by lymphocyte cells B and T. They act with a specific (that is stored) antibody and cellular response to the pathogen. Therefore, the effective strengthening of the immune system allows us to overcome and combat the aggressions of pathogens. This strategy is particularly useful for those who are more susceptible to infectious diseases, such as the elderly, children, and immunodeficient.

Nowadays we have many methods to improve the immune system, both with the use of drugs, or traditional medicine using the extractive or natural substances that the tradition and experience of the people have handed down to us. In particular, we know the effectiveness of many plant extracts, and some macros and microelements, which are used to prevent infections and support our immune system. The list is indeed extensive, and we cannot examine it in this context.

An interesting contribution to the identification of specific substances with immunomodulating activity is presented in the work of S.Maggini, from which we report the following explanatory Table 1 [11].

Epithelial barriers	Cellular immunity	Antibody production
Vitamin A	Vitamin A	Vitamin A
Vitamin C	Vitamin B <sub>6</sub>	Vitamin B <sub>6</sub>
Vitamin E	Vitamin B <sub>12</sub>	Vitamin B <sub>12</sub>
Zinc	Vitamin C	Vitamin D
	Vitamin D	Vitamin E
	Vitamin E	Folic acid
	Folic acid	Zinc
	Iron	Copper
	Zinc	Selenium
	Copper	
	Selenium	

**Table 1.** Synthesis of micronutrient action sites and effects on the immune system

The table shows that the intake of specific vitamins: vitamin A, **B6, B12, C, D, E,** and **Folic acid** and the trace elements **iron,** zinc, copper, and selenium which work in synergy is useful to support the protective activities of the immune cells. [11].

But for these substances to be effective it is essential to know specific nutrient deficiencies that every person needs because improper and indiscriminate use of diet and unnecessary food supplements can be more harmful than useful.

The Hippocrates's aphorism: "makes food your medicine", well expresses this concept.

**Nutrigenomics, Epigenetics, and interaction between food and gene expression, Immunity**

Thanks to the use of Nutrigenomics we are now able to discover, with the execution of genetic targeted tests, what are the nutritional and dietary deficiencies that every individual must fill.

Nutrigenomics studies the interactions between food and DNA, which occur through induction by Nutrients with **epigenetic changes of DNA,** that are stable, reversible changes of DNA, which cause regulation in gene expression, without modifying the original sequence. [12, 13].

*Epigenetic told us that Nutraceuticals have the function of modulators that influence the development and maintenance of the organism.*

The most important interactions between food and DNA are:

- DNA methylation
- Modification of histones
- Expression of Micro RNA

Food substances can influence the epigenetic mechanisms described above, between these DNA and histone methylation and histone acetylation, are the most important and used mechanisms. These interactions can occur through the direct action of food molecules on enzymes that catalyze epigenetic mechanisms or indirectly through alteration of the substrate availability of such enzymes [14-17].

Food molecules that play a key role include folic acid (vitamin B9), cobalamin (vitamin B12), pyridoxine (vitamin B6), riboflavin (vitamin B2), choline (vitamin J), methionine (an amino acid), betaine, serine and zinc that become part of the cycle or as enzymatic cofactors, molecular precursors or methyl group donors. A huge amount of work demonstrates the close link between these microelements and the strengthening of the immune system, we mention only a small part in references [11, 18-32]

### **Microbiome and immune system**

In recent years an increasing interest has been focusing on the important role played by the Microbiome (the complex of microorganisms that colonize our intestines), on the state of general well-being and the functioning of our immune system. Numerous clinical and experimental studies have highlighted the benefits obtainable with the use of **Probiotics**, selected bacterial strains also known as **lactic ferments**, which are administered orally, to colonize and modulate the intestinal flora. [33-39]

Many works and guidelines recommend taking multivitamins, plant extracts, and a good balance of intestinal flora for the efficient functioning of the immune system. Unfortunately, most of the nutrients supplements on the market have the disadvantage of being poorly absorbed and even less assimilated to fully express all their beneficial effects.


In particular, many vitamins and plant extracts have insufficient bioavailability and must be administered following precise indications. [40]

For Probiotics, the main drawback is their poor ability to take root and colonize the intestine. Thanks to pharmaceutical technology, the potential and therapeutic efficacy of these products can be greatly improved.

Among the various pharmaceutical technologies used nowadays, the most promising ones that have shown remarkable versatility are represented by:


### **Microencapsulation, and liposomal technology**

**Microencapsulation** consists of the coating, covering, the nutrients to be administered, with polymers of various nature both extractive and synthetic. This technology allows you to: Improve stability, solubility, Mask the smell and taste of unpleasant substances. (Fig. 2)



**Fig. 2:** Example of Microencapsulated Probiotics - Monocoated Microcapsule

**The Liposomes** are spherical vesicles formed by a double membrane of phospholipidic nature that contains within them the substances to be conveyed. With their hydrophobic, hydrophilic characters and smaller size, they actively deliver the drugs to site of action [41]. By structure and chemical composition, they are very similar to cell membranes with which they have high affinity and ease of absorption and assimilation Fig. 3 [42]



**Fig. 3.** Schematic comparison between Liposome and cell wall


Liposomal technology is widely used in the pharmaceutical field to improve the bioavailability of many drugs, which has a reduced therapeutic index, such as anticancer, antibiotics, vaccines, etc. [3] In this field, the Argentine company Lipotech ([www.lipotech.com.ar](http://www.lipotech.com.ar)) has obtained the most innovative results and has produced *multifunctional liposomes*, capable of transporting several substances simultaneously within the same liposomes, therefore they are registered under the trademark **Probiosomial**.

The advantages obtainable with this technology are manifold: with a single administration, the Probiosomas furnish at the same time the substances that have demonstrated greater immunostimulating efficacy, assuring their complete assimilation, even for active substances that are poorly absorbed.

For over 25 years, Lipotech has been producing liposome nutrients that are used by many multinational food companies, and have shown excellent efficacy and tolerability. [43-50]


In 2016 Lipotech also produced and patented the **LIFERVIT**, patent N 0001423818, which can provide, with liposomes, five substances particularly useful for the immune system.

A survey conducted at the University of Urbino demonstrated the liposomal nature of LIFERVIT and the ability to penetrate cell cultures [51]. (Fig. 4 - Fig. 5)



**Fig. 4:** Observation sample LIFERVIT with T.E.M. Transmission Electron Microscope





**Fig. 5:** Up-Take of the liposome (arrows) in myelocytic cell line U937 TEM micrograph

The substances present in *Lifervit* are Iron sulfate, Vitamin C, Folic Acid, Vitamin B6, and Vitamin B12. The examination of Table 1. and a wide literature show that these 5 substances, together with other very studied substances, are essential for the proper functioning of the immune system. [11, 18-32] As mentioned above, the only drawback is the poor absorption and reduced bioavailability of these nutrients, in particular iron and vitamin B12, if administered as natively. [40, 52]

The liposomal/Probiosomial technology has solved this inconvenience, providing an effective instrument of primary prevention of infectious diseases, with the strengthening of the immune system. Different solutions can be obtained by adapting the content of "immunostimulating" substances to be inserted in liposomes, based on the specific nutrient deficiencies that people need, thus implementing the personalized immunotherapy.

**The dual effectiveness of probiosomial technology and the role of the Microbiome**

The *Lifervit* can exert double effectiveness in the prevention of infectious diseases: the immunostimulating effect, and the protection of the endothelium.

In fact, in addition to expressing safe effectiveness on the immune system, the association between folic acid, vitamin B6 and vitamin B12 present in *Lifervit*, has been shown to improve Homocysteine metabolism, which is a recognized independent cardiovascular risk factor, and is highly damaging to the endothelium, leading to thrombosis.

An important mechanism through which homocysteine promotes thrombosis is that linked to the proliferation of smooth muscle cells of blood vessels, and increased endothelial adhesion, deposition of low-density lipoproteins (LDL) and formation of foamy cells. Homocysteine also acts directly on platelet activation and endovascular aggregation, promoting thrombin formation and endothelial V-factor activation, inhibition of protein C, and reduction of antithrombin III activity. [53-56].

Further evidence on the pathogenic role of homocysteine comes from molecular investigations that have clarified its effect on fundamental proteins such as albumin, fibronectin, transthyretin, and metallothionein. The molecular mechanism involved concerns the binding of homocysteine on these proteins and is defined *S-homocysteinylation*, thus S-homocysteinylation of protein cysteine residues may explain mechanistically the cytotoxicity of elevated L-homocysteine. [56]

Finally, complete work on the effects of hyperhomocysteinemia contains a detailed bibliographical reference on the pathogenic mechanism of arterial occlusion [57], in the following very explanatory Table 2:

Study	Findings*
Boushey et al <sup>124</sup>	5-μmol/L rise in total plasma HC increases relative risk of CAD, CVD, PVD
European Concerted Action Project <sup>125</sup>	HHC associated with increased risk of vascular disease multiplicative to other risk factors
Stampfer et al <sup>136</sup>	Relative risk of MI of 3.1 when HC levels were in the 95th percentile of control values
Malinow et al <sup>137</sup> and Voutilainen et al <sup>127</sup>	Increased plasma HC levels are associated with thickened carotid wall
Nygaard et al <sup>144</sup>	Strong graded relationship between total HC and mortality
Kluijtmans et al <sup>153</sup> and Mudd et al <sup>15</sup>	677C→T MTHFR is a genetic risk for CAD

**Table 2:** Hyperhomocysteinemia and Arterial Occlusive Disease; Citation of some studies that demonstrate correlation

\* HC indicates homocysteine; CAD, coronary artery disease; CVD, cerebrovascular disease; PVD, peripheral vascular disease; HHC, hyperhomocysteinemia; MI, myocardial infarction; and MTHFR, methylenetetrahydrofolate reductase.

From the above CoVID19 and Homocysteine, although following two different routes they have a common pathogenic fate: *endothelial dysfunction and thrombosis*.

*Lifervit* allows simultaneous action on both pathogenic pathways:

- prevention of contagion, CoVID19, promoting the immune system ;
- prevention of thrombosis in patients CoVID19, improving homocysteine metabolism.

*“Our blood vessels are the lifelines for all of our organs. If CoVID-19 damages our vessels, the long-term effects could be devastating even after the virus is cleared. Finding ways to protect our blood vessels and helping them heal could be an important dimension to CoVID-19 treatment. These interventions could involve not only medications but importantly, dietary factors and lifestyle.”* [3]

Another effective tool in the prevention of infectious diseases is provided by the modulation of the **Microbiome**. With the administration of selected microencapsulated bacterial strains, we can positively boost our immune system.

Numerous experimental and clinical controlled studies have demonstrated the usefulness of this approach. [33-39].

## Conclusions

Alongside the traditional therapies most used to combat infectious diseases, we now have effective meaning available that can complement or become of primary importance in cases of failure of the protocols used routinely. With this work, we want to highlight that other promising and safe approaches are possible to combat present and future infectious diseases and to promote well-being and public health, concurrently, or with other available therapies.

Only the clinical experience conducted on a wide range of controlled cases can give us more security in the most effective therapeutic choices in the treatment of infections. In any case, the awareness is growing that there is no single and effective treatment in all situations, and for all patients, precisely as the CoVID19 shows us.

In this regard, if we want to adopt this approach, it is good to remember the importance of a preventive analysis of immune deficits and specific nutrient deficiencies that every person needs, to choose the most effective therapies.

Hematological and genetic tests provide essential support for this purpose and avoid improper and unjustified use of diet, food supplements, or drug therapies of no proven efficacy, which in addition to being expensive can compromise the health of users. Only in this way can each patient have "his" specific therapy.

The mission of Lipotech is to provide the **Probiosomial** technology for the production of customized immunomodulating supplements effective, or other specific needs for primary prevention and general well-being.

## Disclosure

The authors report no conflicts of interest in this work.

## References

1. Ali S, Mahassni S. SH., Alnefaie, RM. The Effects of Hypervitaminosis D in Rats on Histology and Weights of Some Immune System Organs and Organs Prone to Calcification. *International Journal of Pharmaceutical and Phytopharmacological Research.*; 2018; 8(6):59-71.
2. Keri, L., Trully, S., Sandra, M., Jutti, L. Molecular Docking of Quinine, Chloroquine and Hydroxychloroquine to Angiotensin Converting Enzyme 2 (ACE2) Receptor for Discovering New Potential COVID-19 Antidote. *J. Adv. Pharm. Edu. Res.* 2020; 10(2):1-4.
3. Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, Baxter-Stoltzfus A, Laurence J. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. *Translational Research.* 2020 Apr 15.
4. Klok FA, Kruip MJ, Van der Meer NJ, Arbous MS, Gommers DA, Kant KM, Kaptein FH, van Paassen J, Stals MA, Huisman MV, Endeman H. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thrombosis research.* 2020 Apr 10.
5. Sardu C, Gambardella J, Morelli MB, Wang X, Marfella R, Santulli G. Hypertension, thrombosis, kidney failure, and diabetes: Is COVID-19 an endothelial disease? A comprehensive evaluation of clinical and basic evidence. *Journal of clinical medicine.* 2020 May;9(5):1417.
6. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, Vanstapel A, Werlein C, Stark H, Tzankov A, Li WW. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. *New England Journal of Medicine.* 2020 May 21.
7. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H. Endothelial cell infection and endotheliitis in COVID-19. *The Lancet.* 2020 May 2;395(10234):1417-8.
8. Poissy J, Goutay J, Caplan M, Parmentier E, Duburcq T, Lassalle F, Jeanpierre E, Rauch A, Labreuche J, Susen S. Pulmonary embolism in COVID-19 patients: awareness of an increased prevalence. *Circulation.* 2020 Apr 24.
9. Fogarty H, Townsend L, Ni Cheallaigh C, Bergin C, Martin-Loeches I, Browne P, Bacon CL, Gaule R, Gillett A, Byrne M, Ryan K. More on COVID-19 coagulopathy in Caucasian patients. *British Journal of Haematology.* 2020 May 12.
10. Marietta M, Ageno W, Artoni A, De Candia E, Gresele P, Marchetti M, Marcucci R, Tripodi A. COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET). *Blood transfusion= Trasfusione del sangue.* 2020 Apr 8;18(3):167-9.

11. Maggini S, Wintergerst ES, Beveridge S, Hornig DH. Selected vitamins and trace elements support immune function by strengthening epithelial barriers and cellular and humoral immune responses. *British Journal of Nutrition*. 2007 Oct;98(S1):S29-35.
12. Huang SJ, Xu YM, Lau AT. Epigenetic Effects of the 13 Vitamins. *Current Pharmacology Reports*. 2018 Dec 1;4(6):453-67.
13. Beckett EL, Yates Z, Veysey M, Duesing K, Lucock M. The role of vitamins and minerals in modulating the expression of microRNA. *Nutrition research reviews*. 2014 Jun;27(1):94-106.
14. Zhong J, Karlsson O, Wang G, Li J, Guo Y, Lin X, Zemplyenyi M, Sanchez-Guerra M, Trevisi L, Urch B, Speck M. B vitamins attenuate the epigenetic effects of ambient fine particles in a pilot human intervention trial. *Proceedings of the National Academy of Sciences*. 2017 Mar 28;114(13):3503-8.
15. Keat Wei L, Sutherland H, Au A, Camilleri E, Haupt LM, Gan SH, Griffiths LR. A potential epigenetic marker mediating serum folate and vitamin B12 levels contributes to the risk of ischemic stroke. *BioMed research international*. 2015 Feb 1;2015.
16. Simopoulos AP. Genetic variation and dietary response: nutrigenetics/nutrigenomics. *Asia Pacific Journal of Clinical Nutrition*. 2002 Oct;11:S117-28.
17. Vakili S, Caudill MA. Personalized nutrition: nutritional genomics as a potential tool for targeted medical nutrition therapy. *Nutrition reviews*. 2007 Jul 1;65(7):301-15.
18. Ekiz C, Agaoglu L, Karakas Z, Gurel N, Yalcin I. The effect of iron deficiency anemia on the function of the immune system. *The Hematology Journal*. 2005 Jan 1;5(7):579-83.
19. Chandra RK. Iron-zinc, immune responses, and infection. In *NESTLE NUTRITION WORKSHOP SERIES 2001 (Vol. 45, pp. 201-212)*. Philadelphia; Lippincott-Raven; 1999.
20. Calder PC, editor. *Nutrition and immune function*. CABI; 2002.
21. Katona P, Katona-Apte J. The interaction between nutrition and infection. *Clinical Infectious Diseases*. 2008 May 15;46(10):1582-8.
22. Wintergerst ES, Maggini S, Hornig DH. Contribution of selected vitamins and trace elements to immune function. *Annals of Nutrition and Metabolism*. 2007;51(4):301-23.
23. Chandra RK. Nutrition and the immune system: an introduction. *The American journal of clinical nutrition*. 1997 Aug 1;66(2):460S-3S.
24. Lewicki S, Lewicka A, Kalicki B, Kłos A, Bertrandt J, Zdanowski R. The influence of vitamin B12 supplementation on the level of white blood cells and lymphocytes phenotype in rats fed a low-protein diet. *Central-European journal of immunology*. 2014;39(4):419.
25. Mikkelsen K, Stojanovska L, Prakash M, Apostolopoulos V. The effects of vitamin B on the immune/cytokine network and their involvement in depression. *Maturitas*. 2017 Feb 1;96:58-71.
26. Linus Pauling Institute Micronutrient Information Center; *Immunity In-Depth:2015*
27. Todorova TT, Ermenlieva N, Tsankova G. Vitamin B12: Could It Be a Promising Immunotherapy?. *Immunotherapy: Myths, Reality, Ideas, Future*. 2017 Apr 26:85. <http://dx.doi.org/10.5772/65729>
28. Aslam MF, Majeed S, Aslam S, Irfan JA. Vitamins: Key role players in boosting up immune response—A mini review. *Vitam. Miner*. 2017;6:153.
29. *Vitamins and Minerals; Mayo Clinic Women' S Health Source, Special Report July 2009.*
30. Riccardi, B. Iron Integration in Anaemias and New Pharmaceutical Technologies, Correlation between Pharmaceutical Iron Technology and the Effectiveness of Supplements, *Journal of Nutraceuticals and Food Science*, 4(2):1.
31. Choi SW, Friso S. Epigenetics: a new bridge between nutrition and health. *Advances in nutrition*. 2010 Nov;1(1):8-16. doi:10.3945/an.110.1004.
32. Ames BN, Elson-Schwab I, Silver EA. High-dose vitamin therapy stimulates variant enzymes with decreased coenzyme binding affinity (increased  $K_m$ ): relevance to genetic disease and polymorphisms. *The American journal of clinical nutrition*. 2002 Apr 1;75(4):616-58.
33. Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett CM, Knight R, Gordon JI. The human microbiome project. *Nature*. 2007 Oct;449(7164):804-10.
34. Tibbs TN, Lopez LR, Arthur JC. The influence of the microbiota on immune development, chronic inflammation, and cancer in the context of aging. *Microbial Cell*. 2019 Aug 5;6(8):324.
35. Marcos A, Nova E, Montero A. Changes in the immune system are conditioned by nutrition. *European journal of clinical nutrition*. 2003 Sep;57(1):S66-9.
36. Lazar V, Ditu LM, Pircalabioru GG, Gheorghe I, Curutiu C, Holban AM, Picu A, Petcu L, Chifiriuc MC. Aspects of gut microbiota and immune system interactions in infectious diseases, immunopathology, and cancer. *Frontiers in immunology*. 2018 Aug 15;9:1830.
37. Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. *Cell*. 2005 Jul 15;122(1):107-18.
38. Schertzer JD, Steinberg GR. Immunometabolism: the interface of immune and metabolic responses in disease. *Immunology and Cell Biology*. 2014 Apr;92(4):303-



39. Mezouar S, Chantran Y, Michel J, Fabre A, Dubus JC, Leone M, Sereme Y, Mège JL, Ranque S, Desnues B, Chanez P. Microbiome and the immune system: From a healthy steady-state to allergy associated disruption. *Human Microbiome Journal*. 2018 Dec 1;10:11-20.
40. Blumberg JB, Cena H, Barr SI, Biesalski HK, Dagach RU, Delaney B, Frei B, González MI, Hwalla N, Lategan-Potgieter R, McNulty H. The use of multivitamin/multimineral supplements: a modified delphi consensus panel report. *Clinical therapeutics*. 2018 Apr 1;40(4):640-57.
41. MP SC, Prasobh GR, Jaghatha T, Aswathy BS, Remya SB. An Overview on Liposomal Drug Delivery System. *Int. J. Pharm. Phytopharm. Res.* 2019 Apr; 9(2):61-8.
42. Bozzuto G, Molinari A. Liposomes as nanomedical devices. *International journal of nanomedicine*. 2015;10:975.
43. Coelho JF, Ferreira PC, Alves P, Cordeiro R, Fonseca AC, Góis JR, Gil MH. Drug delivery systems: Advanced technologies potentially applicable in personalized treatments. *EPMA journal*. 2010 Mar;1(1):164-209.
44. Gotelli CA, Gotelli MJ, Boccio JR, Zubillaga MB, Caro RA, Garcia del Rio H, Weill R. Bioavailability of microencapsulated ferrous sulfate in fluid milk studies in human beings. *Acta physiol. pharmacol. ther. latinoam*. 1996:239-45.
45. Eakins JD, Brown DA. An improved method for the simultaneous determination of iron-55 and iron-59 in blood by liquid scintillation counting. *The International journal of applied radiation and isotopes*. 1966 Jul 1;17(7):391-7.
46. Uicich R, Pizarro F, Almeida C, Díaz M, Carmuega E, O'Donnell A. Absorción de hierro de leche de vaca, fluida, fortificada con sulfato ferroso encapsulado. *Med. infant*. 1996:9-13.
47. BOCCIO JR, ZUBILLAGA MB, CARO RA, GOTELLI CA, GOTELLI MJ, WEILL R. New procedure to fortify fluid milk and derivatives with iron: a comparative study in mice. *Journal of nutritional science and vitaminology*. 1995;41(6):619-26.
48. Boccio JR, Zubillaga MB, Caro RA, LYSIONEK AE, SALGUEIRO MJ, CALMANOVICI GP, SARABIA MI, WEILL R. Microencapsulated ferrous sulfate to fortify cow milk: absorption and distribution in mice. *Journal of nutritional science and vitaminology*. 1998;44(3):381-9.
49. Zubillaga MB, Caro RA, Boccio J, Gotelli CA, Gotelli MJ, Weill R. New procedure to fortify fluid milk with iron: metabolic and biochemical study in rats. *Nutrition Research*. 1996 Jan 1;16(1):131-7.
50. Uicich R, Pizarro F, Almeida C, Díaz M, Boccio J, Zubillaga M, Carmuega E, O'Donnell A. Bioavailability of microencapsulated ferrous sulfate in fluid cow's milk. *Studies in human beings. Nutrition research*. 1999 Jun 1;19(6):893-7.
51. Rapetti MC, Donato H, de Galvagni A, Lubovitsky M, Lanzilotta M, Trepacka E, Burlando G, Weill R. Correction of iron deficiency with an iron-fortified fluid whole cow's milk in children: results of a pilot study. *Journal of pediatric hematology/oncology*. 1997 May 1;19(3):192-6.
52. European Food Safety Authority. Tolerable upper intake levels for vitamins and minerals. *Scientific Committee on Food*. 2006.
53. Glushchenko AV, Jacobsen DW. Molecular targeting of proteins by L-homocysteine: mechanistic implications for vascular disease. *Antioxidants & redox signaling*. 2007 Nov 1;9(11):1883-98.
54. Büdy B, O'Neill R, DiBello PM, Sengupta S, Jacobsen DW. Homocysteine transport by human aortic endothelial cells: identification and properties of import systems. *Archives of biochemistry and biophysics*. 2006 Feb 15;446(2):119-30.
55. Škovierová H, Vidomanová E, Mahmood S, Sopková J, Drgová A, Červeňová T, Halašová E, Lehotský J. The molecular and cellular effect of homocysteine metabolism imbalance on human health. *International journal of molecular sciences*. 2016 Oct;17(10):1733.
56. Jakubowski H. Homocysteine modification in protein structure/function and human disease. *Physiological reviews*. 2019 Jan 1;99(1):555-604.
57. Eldibany MM, Caprini JA. Hyperhomocysteinemia and thrombosis: an overview. *Archives of pathology & laboratory medicine*. 2007 Jun;131(6):872-84.